secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002862
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE updates corporate presentation with previously announced Phase 1a data for VYN202
--------------------------------------------------------------------------------

- Phase 1a data for VYN202 and pipeline program updates included in presentation; data was previously announced.
- Presentation posted on company website and filed as Exhibit 99.1 on January 13, 2025.
- No new financial results or material events disclosed in this 8-K filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/0001104659-25-002862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925002862/tm252956d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer